Every value below carries the sentence it was read from.
733 sources stand behind the page.
Field
Value
Cited text
Known as
Azacitidine
“Eligible subjects with NPM1 MRD positivity will receive oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day,...” NCT04689815 ↗694
“This is a multicenter, nonrandomized, open-label phase 2 study (with a safety run-in phase) of azacitidine (AZA) 75 mg/m2 given IV or SQ on days 1-7 every 28 days in...” NCT02845297 ↗
“Participants will receive standard low-intensity therapy (LIT) regimens for newly diagnosed AML, which may include venetoclax combined with either azacitidine, decitabine, or...” NCT07014462 ↗
“A Single-arm, Single-center Clinical Trial Evaluating the Efficacy and Safety of a Regimen Combining Chidamide With Venetoclax, Azacitidine, and Homoharringtonine in the...” NCT07643636 ↗
“Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3,...” NCT03709576 ↗
“Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of abnormal cells, either by killing the cells or by stopping them from dividing.” NCT00398047 ↗
“Onureg (CC-486, oral azacitidine) will be administered orally at 200 or 300 mg once daily for 7 or 14 consecutive days, beginning on Day 1 of repeated 28-day cycles.” NCT05782127 ↗
“Azacitidine 75 mg/m2 Subcutaneous (SC) or IV Daily with a continuous 7-day scheme or on a 5-on/2-off [weekend]/2-on schedule (5-0-2) in 28-day cycle” NCT07082452 ↗
“Drug: Azacitidine
Tablets or capsules for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration” NCT04608110 ↗
“Azacitidine (5-azacytidine) is a nucleoside metabolic inhibitor that has been US Food and Drug Administration-approved for several MDS subtypes.” NCT04609826 ↗
“5'-azacitadine will be given at a low dose of 32mg/m2 S.C for 5 days every 28 days (a cycle).” NCT01995578 ↗
Known as
5-aza
“participants with recurrent and/or metastatic (R/M) HNSCC were treated with low-dose 5-azacytidine (5-aza) daily for either 5 or 10 days in combination with durvalumab and...” PMID 40091844 ↗Mar 20254
“The BCL2 inhibitor venetoclax (VEN) in combination with azacitidine (5-AZA) is currently transforming acute myeloid leukemia (AML) therapy.” PMID 36892565 ↗Jun 2023
“the deoxyribonucleic acid (DNA) methyltransferase inhibitor, 5-azacitidine (5-AZA)” NCT01207726 ↗
“5-Azacitidine (5 AZA) in subjects with myelodysplastic syndrome (MDS)” NCT01828346 ↗
“5-Azacitidine(5-AZA) is the most promising drug for treatment MDSs.” NCT00897130 ↗
Known as
5-azacitidine
“To investigate its mechanism of action, we performed integrative expression and methylation analysis of 63 cancer cell lines (breast, colorectal, and ovarian) after treatment...” PMID 24583822 ↗Feb 201423
“The purpose of this study is to learn if 5'-Azacitidine will help to lower the risk of the disease coming back after a stem cell transplant in patients with MDS and AML.” NCT01995578 ↗
“Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)” NCT00422890 ↗
“Demethylation drugs, such as 5-azacitidine (AZA) and 5-aza-2-deoxycytidine (decitabine), can inhibit DNA methyltransferase” NCT03978364 ↗
“the deoxyribonucleic acid (DNA) methyltransferase inhibitor, 5-azacitidine (5-AZA)” NCT01207726 ↗
“5-Azacitidine (Azacitidine) is a nucleoside analogue chemotherapy drug” NCT07404332 ↗
“5-Azacitidine(5-AZA) is the most promising drug for treatment MDSs.” NCT00897130 ↗
ClinicalTrials.gov intervention name — accepted as the source's own labelNCT00422890 ↗
Known as
5-azacytidine
“The goal of this clinical research study is to find the highest tolerable dose of Azacytidine (5-azacytidine) combined with cytosine arabinoside (ara-C) for the treatment of...” NCT00569010 ↗5
“participants with recurrent and/or metastatic (R/M) HNSCC were treated with low-dose 5-azacytidine (5-aza) daily for either 5 or 10 days in combination with durvalumab and...” PMID 40091844 ↗Mar 2025
“Drug2: Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DeoxyriboNucleic Acid methyltransferases at low doses, resulting in gene promoter...” NCT05426798 ↗
“Azacitidine (5-azacytidine) is a nucleoside metabolic inhibitor that has been US Food and Drug Administration-approved for several MDS subtypes.” NCT04609826 ↗
“5-Azacytidine is designed to activate ("turn on") certain genes in cancer cells whose job is to fight tumors.” NCT01254890 ↗
“The hypomethylating agent azacitidine (also known as 5-azacytidine or Vidaza®).” NCT02750995 ↗
“This study is a prospective, single-center, single-arm clinical study, which plans to enroll 40 patients with high-risk myelodysplastic syndrome (MDS) to be given azacitidine...” NCT06279338 ↗69
“Herein, we present the phase 1a dose escalation data of IO-202 as monotherapy and in combination with azacitidine (AZA) in patients with relapsed/refractory (R/R) acute myeloid...” PMID 40919482 ↗Jun 2025
“In this phase 1 study, azacitidine (AZA) was given before high-dose cytarabine (HiDAC) and mitoxantrone (mito) based on the hypothesis that epigenetic priming with a...” PMID 32074275 ↗Feb 2020
“This research is being done to study the efficacy and safety of unrelated umbilical cord blood stem cell microtransplantation combined with azacitidine(AZA) based treatment for...” NCT05584761 ↗
“This single arm, prospective study on the feasibility of a bridging treatment with low-dose azacitidine (AZA) in combination with short term CAG derived regimen prior to...” NCT04216355 ↗
“This is a multicenter, nonrandomized, open-label phase 2 study (with a safety run-in phase) of azacitidine (AZA) 75 mg/m2 given IV or SQ on days 1-7 every 28 days in...” NCT02845297 ↗
“Based on the efficacy data of venetoclax (VEN)-based treatment in NPM1mut AML older patients, we retrospectively analysed the off-label combination of VEN plus azacitidine...” PMID 37226312 ↗May 2023
“This study will assess the adverse events and changes in the disease activity when Pivekimab Sunirine (PVEK) is given in combination with Venetoclax (VEN) and Azacitidene (AZA)...” NCT07581002 ↗
“To investigate its mechanism of action, we performed integrative expression and methylation analysis of 63 cancer cell lines (breast, colorectal, and ovarian) after treatment...” PMID 24583822 ↗Feb 2014
“We designed a phase 1/2 clinical trial to examine the safety/efficacy of the protein synthesis inhibitor omacetaxine mepesuccinate (oma) with the hypomethylating agent (HMA)...” PMID 41140451 ↗Oct 2025
“a novel biomodulatory treatment regimen consisting of low-dose azacitidine (AZA) in combination with PPARγ agonist pioglitazone (PGZ) and all-trans retinoic acid (ATRA) induced...” PMID 30542286 ↗Nov 2018
“This study will assess the adverse events and changes in the disease activity when Pivekimab Sunirine (PVEK) is given in combination with Venetoclax (VEN) and Azacitidene (AZA)...” NCT07581002 ↗
Known as
azacitidin
“decitabine or azacitidin (AZA), producing complete remission (CR) plus CR with incomplete hematologic recovery (CRi) rates of 74% and 66.7%, respectively, in previously...” NCT04824924 ↗
“The goal of this clinical research study is to find the highest tolerable dose of Azacytidine (5-azacytidine) combined with cytosine arabinoside (ara-C) for the treatment of...” NCT00569010 ↗3
“Hypomethylating agents (HMA) like azacytidine (AZA) and decitabine (DEC), have been shown to improve survival or delay disease progression in high-risk MDS.” NCT06004765 ↗
“Platzbecker et al. applied azacytidine (AZA) monotherapy to AML patients with continuous MRD positive after combined chemotherapy.” NCT05361057 ↗
“VIALE-M is a randomized, double-blind, two-arm study to evaluate the safety and efficacy of venetoclax in combination with oral azacitidine (CC-486) as maintenance therapy in...” PMID 35852098 ↗Jul 20227
“The purpose of this study is to evaluate the standard treatment, azacitidine (Vidaza) given as an injection under the skin compared to the same medication (called CC-486) taken...” NCT03493646 ↗
“Onureg (CC-486, oral azacitidine) will be administered orally at 200 or 300 mg once daily for 7 or 14 consecutive days, beginning on Day 1 of repeated 28-day cycles.” NCT05782127 ↗
“a regimen combining oral azacitidine (CC-486) and nivolumab in patients with Hodgkin lymphoma (HL) refractory to PD1/PD-L1 therapy.” NCT05162976 ↗
“CC-486 (5-azacitidine) with a dose of 300mg oral intake daily will be given on day 1 to day 10 for 6 cycles.” NCT04447027 ↗
“Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients” NCT06180863 ↗
“with oral azacitidine (CC-486)-CHO(E)P vs CHO(E)P in previously untreated peripheral T-cell lymphomas” NCT04803201 ↗
“Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in...” NCT07463768 ↗2
“Oral Azacitidine, 300mg PO Daily during days 1-14 of a 28 day cycle for up to 6 cycles.” NCT06370000 ↗
Known as
Oral-AZA
“In the phase 3 QUAZAR AML-001 trial (NCT01757535) of patients with acute myeloid leukaemia (AML) in remission following intensive chemotherapy (IC) and ineligible for...” PMID 37952982 ↗Nov 2023
Known as
Vidaza
“The purpose of this study is to determine if the addition of a drug called azacitidine (Vidaza®)when added to carboplatin and paclitaxel will change the genetic material of the...” NCT00842582 ↗18
“Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)” NCT00422890 ↗
“A Phase I/II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (Vidaza®) in Intermediate-2 and High Risk MDS Patients” NCT01305460 ↗
“Azacitidine (VIDAZA) for Injection:100 mg per vial, subcutaneous injection will be administered for 7 days in each 28 day cycle” NCT04511975 ↗
“Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL” NCT01241786 ↗
“azacitidine (also known as Vidaza®) was a current standard of care treatment option in the United States.” NCT02752035 ↗
“Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane)” NCT00748553 ↗
“Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)” NCT03182894 ↗
“Azacitidine (Vidaza®) will be administered similarly to group 1 exposed above.” NCT01342692 ↗
“Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza).” NCT01453140 ↗